On the 19th, Zheng Zhongwei, head of the vaccine research and development team of the scientific research team of the joint prevention and control mechanism of the State Council, said that China’s vaccine research and development team took action from the beginning of the emergence of the Omicron mutant. At present, positive progress has been made in the research and development of monovalent and multivalent vaccines for Omicron mutant strains. Preclinical research has been completed with relatively rapid progress, and application materials for clinical trials are being submitted to the State Drug Administration.
On the 20th, Zhang Wenhong, director of the national infectious diseases Medical Center, said that the current situation of epidemic prevention in China is grim. It is very important to continue to improve the vaccination rate and strengthen the reserve of covid-19 therapeutic drugs. It is also necessary to reserve medical resources.
Citic Securities Company Limited(600030) research department believes that under the “dynamic clearing” policy, China still needs to promote covid-19 vaccination. Due to the large number of mutation sites of Omicron gene and the significant increase of transmission capacity, only completing the first complete vaccination procedure can not meet the requirements of epidemic prevention. Therefore, the demand for the third booster vaccination will continue in the future. With reference to influenza vaccine, it is estimated that the market of booster injection can reach 15 billion yuan.
Citic Securities Company Limited(600030) optimistic about investment opportunities in the vaccine sector. According to the current severe rate deduction, Omicron has a high probability of flooding. Referring to the influenza vaccine market, the demand for vaccines has a certain sustainability, and the valuation of relevant enterprises is expected to be reshaped. It is suggested to pay attention to Chongqing Zhifei Biological Products Co.Ltd(300122) (recombinant protein covid-19 vaccine EUA, approved heterologous sequential vaccination products in Indonesia and China, acting as a continuous dose of HPV), Cansino Biologics Inc(688185) (approved dose of single shot adenovirus vector covid-19 vaccine, approved heterologous sequential vaccination booster in China), Walvax Biotechnology Co.Ltd(300142) (cooperating with Aibo to develop mRNA pathway covid-19 vaccine, which is currently in phase III of clinical trial) Shenzhen Kangtai Biological Products Co.Ltd(300601) (the highest neutralizing antibody titer ratio among inactivated vaccines in China). In terms of time catalyst, it is suggested to pay attention to the inhalation dosage form of Cansino Biologics Inc(688185) and the interim analysis data of Watson mRNA phase III. At the same time, it is suggested to pay attention to the influenza vaccine sector of policy immunization, Changchun Bcht Biotechnology Co(688276) , Jiangsu Gdk Biological Technology Co.Ltd(688670) , Hualan Biological Engineering Inc(002007) and other sectors are expected to get out of the independent market.
